title: [Diagnosis and management of esophageal chest pain].
abstract: Esophageal pain that manifests as heartburn or chest pain, is a prevalent problem. Esophageal chest pain is most often caused by gastroesophageal reflux disease (GERD), but can also result from inflammatory processes, infections involving the esophagus, and contractions of the esophageal muscle. The mechanisms and pathways of esophageal chest pain are poorly understood. Vagal and spinal afferent pathways carry sensory information from the esophagus. Recently, esophageal hypersensitivity is identified as an important factor in the development of esophageal pain. A number of techniques are available to evaluate esophageal chest pain such as endoscopy and/or proton-pump inhibitor trial, esophageal manometry, a combined impedance-pH study, and esophageal ultrasound imaging. Proton pump inhibitors (PPIs) have the huge success in the treatment of GERD. Other drugs such as imipramine, trazadone, sertraline, tricyclics, and theophylline have been introduced for the control of esophageal chest pain in partial responders to PPI and the patients with esophageal hypersensitivity. Novel drugs which act on different targets are anticipated to treat esophageal pain in the future.
authors.affiliation: Department of Internal Medicine, Soonchunhyang University School of Medicine, Bucheon, Korea. sjhong@schbc.ac.kr
authors.forename: Su Jin
authors.initials: SJ
authors.lastname: Hong
mesh_terms: D002637:Chest Pain / Q000209:etiology*; D050782:Esophageal pH Monitoring; D005764:Gastroesophageal Reflux / Q000175:diagnosis* / Q000000981:diagnostic imaging / Q000188:drug therapy; D006801:Humans; D008365:Manometry; D054328:Proton Pump Inhibitors / Q000627:therapeutic use; D014463:Ultrasonography
chemical_list: D054328:Proton Pump Inhibitors